Previous Close | 5.20 |
Open | 4.77 |
Bid | 4.00 |
Ask | 5.10 |
Strike | 40.00 |
Expire Date | 2024-07-19 |
Day's Range | 4.77 - 5.20 |
Contract Range | N/A |
Volume | |
Open Interest | 5.64k |
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that late-breaking data from the ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) were presented at the American Thoracic Society (ATS) 2024 International Conference in San Diego. Data from ARISE evaluating patients with newly diagnosed or recurrent nontuberculous mycobacterial (NTM) lung infection caused by Mycob
On May 17, 2024, Martina Flammer, Chief Medical Officer of Insmed Inc (NASDAQ:INSM), sold 4,642 shares of the company.
As you might know, Insmed Incorporated ( NASDAQ:INSM ) recently reported its quarterly numbers. The results weren't...